Figure 2. Network of Studies – Monthly Migraine Days (Extracted from ICER [2018], p.197).

Figure 2Network of Studies – Monthly Migraine Days (Extracted from ICER [2018], p.197)

Source: Institute for Clinical and Economic Review.19

From: Appendix 8, Summary of Indirect Comparisons

Cover of Clinical Review Report (Resubmission): OnabotulinumtoxinA (BOTOX)
Clinical Review Report (Resubmission): OnabotulinumtoxinA (BOTOX): (Allergan Inc.): Indication: For the prophylaxis of headaches in adults with chronic migraine (≥ 15 days per month with headache lasting four hours a day or longer) [Internet].
Copyright © 2019 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.